Abstract
The use of nonviral gene transfer methods in primary lymphocytes has been hampered by low gene transfer efficiency and high transfection-related toxicity. In this report, high gene transfection efficiency with low transfection-related toxicity was achieved by electroporation using in vitro-transcribed mRNA. Using these methods, >90% transgene expression with >80% viable cells was observed in stimulated primary human and murine T lymphocytes transfected with GFP or mCD62L. Electroporation of unstimulated human PBMCs or murine splenocytes with GFP RNA yielded 95 and 56% GFP+ cells, respectively. Electroporation of mRNA for NY-ESO-1, MART-1, and p53 antigen-specific TCRs into human T lymphocytes redirected these lymphocytes to recognize melanoma cell lines in an MHC-restricted manner. The onset of gene expression was rapid (within 30 min) and durable (up to 7 days postelectroporation) using both GFP and TCR-mediated recognition of target cells. There was no adverse effect observed on the T lymphocytes subjected to RNA electroporation evaluated by cell growth rate, annexin-V staining of apoptotic cells, BrdU incorporation, tumor antigen-specific recognition or antigen-specific TCR affinity. The results of this study indicate that mRNA electroporation provides a powerful tool to introduce genes into both human and murine primary T lymphocytes.
Original language | English |
---|---|
Pages (from-to) | 151-159 |
Number of pages | 9 |
Journal | Molecular Therapy |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2006 |
Externally published | Yes |
Bibliographical note
Funding Information:Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Funding
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Funders | Funder number |
---|---|
National Institutes of Health | |
National Cancer Institute | Z01SC003800 |
Keywords
- Electroporation
- T lymphocytes
- Transfection
- mRNA